VTRS

Bullish

U.S. FDA accepts Viatris new drug application for fast-acting meloxicam for the treatment of moderate-to-severe acute pain

The U.S. FDA has accepted Viatris's new drug application (NDA) for a fast-acting meloxicam intended for the treatment of moderate-to-severe acute pain...

marketscreener.com 1 week ago 0

Bullish

FDA accepts Viatris application for fast-acting meloxicam

The FDA has accepted Viatris Inc.'s New Drug Application for MR-107A-02, a fast-acting meloxicam formulation for moderate-to-severe acute pain. This n...

Investing.com 1 week ago 0

Bullish

Earnings Flash (VTRS) Viatris Inc. Reports Q1 Revenue $3.52B, vs. FactSet Est of $3.36B

Viatris Inc. (VTRS) announced its Q1 revenue reached $3.52 billion, surpassing the FactSet estimate of $3.36 billion. The company, a global healthcare...

www.marketscreener.com 2 weeks ago 0

Bullish

Viatris sets June 17 payment for $0.12 a share quarterly dividend

Viatris (Nasdaq: VTRS) announced a quarterly dividend of $0.12 per share, declared on May 4, 2026. The dividend is scheduled to be paid on June 17, 20...

Stock Titan 3 weeks ago 0